NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Cardiff Oncology, Inc. (CRDF) Stock Analysis

Cardiff Oncology, Inc. (CRDF) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

CRDF

$1.09

+$0.01 (+0.93%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare CRDF with… →

CRDF Key Statistics

As of Sep 4, 2026
Trading
Open
$1.08
Previous Close
$1.08
Day's Range
1.07–1.10
52-Week Range
0.76–3.31
Volume
437.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.46
Valuation
Market Cap
$84.80M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
166.92
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.60
Financials (FY)
Revenue (FY)
$593.00K−13.18%
Net Income (FY)
−$45.85M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
77.80M
1-Year Return
−48.83%
Dividend and dates
Earnings Date
November 12, 2026estimated
Avg Volume
1.24M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

CRDF Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−61.21%
2025−35.25%
2024+193.24%
2023+5.71%
2022−76.71%
2021−66.59%
2020+1350.81%
2019−61.01%
2018−85.75%
2017−85.24%
2016 (partial year)−61.40%

As of September 4, 2026.

CRDF Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$593.00K−$45.85M−7732.0%
2024$683.00K−$45.43M−6651.7%
2023$488.00K−$41.44M−8492.0%
2022$386.00K−$38.70M−10026.9%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$593.00K—−$48.96M−$45.85M−7732.0%
2024$683.00K—−$48.65M−$45.43M−6651.7%
2023$488.00K—−$45.41M−$41.44M−8492.0%
2022$386.00K—−$39.90M−$38.70M−10026.9%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

CRDF Valuation vs Biotechnology Median

Median of 656 stocks
MetricCRDFBiotechnology medianvs median
P/S ratio166.9215.2610.9x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Cardiff Oncology, Inc. (CRDF) is capitalised at $84.80M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 30 employees.

Over the past 52 weeks the price has ranged from $0.76 to $3.31. CRDF last closed at $1.09 on September 4, 2026. That is +$0.01 (+0.93%) against the previous close. The latest close sits 43.42% above that 52-week low.

Financial Health

In fiscal 2025, Cardiff Oncology, Inc. reported revenue of $593.00K. That is −13.18% against the prior fiscal year, when revenue was $683.00K. The same year closed with a net loss of $45.85M. The reported profit margin is 0%. Trailing earnings per share are −0.6.

Across the 4 fiscal years on file, revenue moves from $386.00K in 2022 to $593.00K in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 166.92 times revenue. On price-to-sales that is 10.9 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 1.46. Daily returns over the trailing 10 years annualize to a volatility of 106.42%. Over the trailing twelve months the price has returned −48.83%. Across 10 years the annualized return works out at −43.96%.

Growth & Income

No dividend is on file for CRDF.

Across the complete calendar years on file, 2020 returned +1,350.81% and 2018 returned −85.75%. Of the 9 complete calendar years on file, 3 finished higher. 2026 is still running; the price is −61.21% year to date.

Peer Comparison

Cardiff Oncology, Inc. (CRDF) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Cardiff Oncology, Inc. CRDF $84.80M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Cardiff Oncology, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Cardiff Oncology, Inc.

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers in the United States. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, metastatic triple negative breast cancer, and chronic myelomonocytic leukemia; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with FOLFIRI and bevacizumab or FOLFOX and bevacizumab for the treatment of patients confirmed metastatic and unresectable colorectal cancer in patients with a KRAS or NRAS mutation; and TROV-054, a Phase 1b/2 single-arm clinical trial in KRAS-mutated metastatic colorectal cancer. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Visit website →